14 - 20 January 2017
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts
Coping better with long-term conditions
A study of people with MS or other long-term conditions found that the ability to cope with disability was more associated with quality of life and satisfaction with social roles than with the effect on physical function.
Source: National MS Society (USA)
MS Trust link: Personal stories of living with MS
Hollyoaks MS storyline
A character in the Channel 4 soap Hollyoaks has been diagnosed with MS. The actress Jessica Fox talks about preparing for the storyline and Kirsty Grice, a woman with MS who worked with the production team, talks about her own experience of diagnosis.
MS Trust link: Hollyoaks set to tackle MS storyline
Tysabri and PML
An Italian study looked at characteristics of 39 people taking Tysabri (natalizumab) who developed the brain infection, PML. There was much variety in the number of infusions before the infection appeared and in the age of the people affected. Most were diagnosed after showing symptoms, though one in six were diagnosed with PML from MRI scans.
Source: MS News Today
MS Trust link: PML (Progressive multifocal leukoencephalopathy)
Genes and risk of MS in families
A study of female first degree relatives of people with MS. Risk was calculated by whether people were smokers, looking at their BMI, history of infectious mononucleosis and vitamin D levels, and screening for genes associated with MS risk. Those with the highest risk of MS were more likely to show potential MS activity in neurological examinations and MRI scans although none had been diagnosed with MS or showed any symptoms of the condition.
Source: Medpage Today
MS Trust link: Risk of developing MS
Relapse risk when switching from Gilenya to Lemtrada
A study of real life experiences of MS treatments found that a quarter (nine out of 36) of people had had relapses after switching from Gilenya (fingolimod) to Lemtrada (alemtuzumab). The researchers suggest that this may be due to the way Gilenya works. Most of the nine stabilised after their second course of Lemtrada
Source: Clinical Neurology News
MS Trust link: MS Decisions - a guide to the disease modifying drugs for relapsing MS